The US Food and Drug Administration (FDA) on Monday finalized guidance to pharmaceutical and biotech sponsors looking for more advice on when non-inferiority studies demonstrating effectiveness of an ...

The European Medicines Agency (EMA) is proposing a new guideline on sponsors’ use of non-inferiority designs to assess the safety and effectiveness of new drugs in clinical trials. The proposal aims ...

Topline phase 3 OPUS-1 data show VAX-31 met coprimary immunogenicity endpoints, demonstrating noninferiority and superiority for key pneumococcal serotypes.

Eli Lilly has presented detailed results from the Phase III ACHIEVE-4 trial showing its oral GLP-1 receptor agonist Foundayo ...

Vaxcyte's stock has skyrocketed as its invasive pneumococcal disease (IPD) and pneumococcal pneumonia vaccine has met its ...

Purpose To summarize the characteristics and methodology of non-inferiority trials in ophthalmology, aiding researchers in understanding the applications and limitations of such trials in ophthalmic ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Please provide your email address to receive an email when new articles are posted on . Noninferiority trials test whether a new treatment is not less efficacious than an already approved therapy.

Functional impairments, fatigue, and pain in newly diagnosed solid-tumors: Retrospective path analysis.